BTIG cuts Boston Scientific stock price target on weaker outlook
BTIG cuts Boston Scientific stock price target on weaker outlook
BOSTON SCIENTIFIC CO (BSX) is drawing unusual attention today. Our newswire has captured 20 stories on BSX across 13 sources in the last 36 hours, with AI sentiment reading mixed (avg 49/100).
Boston Scientific Co (BSX) is moving lower today after hitting a 52-week low. The stock opened with a small gap higher but quickly reversed course amid broader market concerns and profit-taking. The decline follows a string of analyst price target reductions and a deteriorating sentiment trend.
Boston Scientific fell to a 52-week low on Wednesday as Wall Street concerns and profit-taking sent the stock lower. The stock opened at $43.35, a 0.7% gap up from the previous close, but failed to hold that level. By the end of the session, the stock had settled near $44.57, with a high of $45.45 and a low of $43.04. The stock traded on 4.0 million shares, which is just 0.2 times the 3-month daily average. The recent price action has seen the stock fall 2.4% over the last 8 sessions, from $45.66 to $44.57.
Analysts have maintained positive ratings on the stock but have lowered their price targets. Mizuho, RBC Capital, Needham, and Evercore ISI Group all maintain Outperform or Buy ratings but have reduced their price targets to between $57 and $85. Boston Scientific reported a trailing twelve-month revenue increase of 17.4% and a net margin of 17.3%, but its beta of 0.58 indicates it has been less volatile than the broader market.
The stock’s 52-week range is $42.25 to $109.50, and it is currently trading near the lower end of that range. Unusual options activity has been observed, with $360K in call premium and $269K in put premium traded, the largest single print being $360K. On July 16, the stock printed one fresh 52-week low. Recent insider transactions show three directors buying shares totaling $554K in the last 90 days. Meanwhile, recent congressional trades include both buys and sells, with Rep. Ro Khanna disclosing a recent purchase of $1,001-$15,000.
Boston Scientific does not have an upcoming earnings date listed. Investors should monitor the breadth of analyst coverage and any further price target adjustments.
AI-assisted analysis composed exclusively from headlines and data on the Top Tier newswire. Not financial advice.
BTIG cuts Boston Scientific stock price target on weaker outlook
Boston Scientific Corp (NYSE:BSX, XETRA:BSX) reported second quarter results that exceeded analyst expectations for revenue and adjusted earnings, while raising its full-year sales outlook. The medical device company posted adjusted earnings per share of $0.86, ahead of the $0.83 consensus...
Boston Scientific (BSX) Q2 2026 earnings call: Q2 results, lowered 2026 guidance, WATCHMAN/EP pressures, and $500M restructuring plan.
Boston Scientific Corporation (BSX) Q2 2026 Earnings Call July 29, 2026 8:00 AM EDTCompany ParticipantsLauren Tengler - Director of Investor...
Boston's tempered 2026 outlook is likely due in part to its recently announced plans to initiate a global restructuring programme.
Comprehensive up-to-date news coverage, aggregated from sources all over the world by Google News.
The medical device maker topped second-quarter expectations but now sees full-year adjusted EPS of $3.28 to $3.32, down from a prior range of $3.34 to $3.41
Comprehensive up-to-date news coverage, aggregated from sources all over the world by Google News.
Boston Scientific (BSX) stock falls after the company
2026-07-29. The following slide deck was published by Boston Scientific Corporation in conjunction with their 2026 Q2 earnings call.
BOSTON SCIENTIFIC CO (BSX) is drawing unusual attention today. Our newswire has captured 20 stories on BSX across 13 sources in the last 36 hours, with AI sentiment reading mixed (avg 49/100). The most recent driver: "BTIG cuts Boston Scientific stock price target on weaker outlook" (Investing.com Analyst Ratings).
Top Tier Newswire does not give financial advice. Our AI sentiment across the last 36 hours of BSX coverage reads 49/100 over 20 stories; treat it as a research signal and do your own diligence.
The data sections refresh continuously as the newswire lands coverage; the written analysis is published once per trading day. Pro subscribers additionally get real-time push alerts, watchlists, and the full live terminal.
More on BSX: full news and sentiment history. Sentiment scores are AI-derived research signals, not financial advice.
Earlier BSX move explainers: 2026-07-16